Review Papers Against Their Own Results

 Long Explanation Copied

Evidence and Scope

The 2012 review by Bissinger et al. (MedChemComm, Pfizer) synthesizes how metabolic soft-spot identification guides medicinal chemistry: lowering lipophilicity, fluorination, deuteration, site-blocking, and eliminating reactive metabolites Metabolism-guided drug design review. The text cites CYPs as responsible for 60–80% of marketed drug metabolism and notes reduced PK-related attrition from ADME integration. Key quantitative examples include: fluorination of an A2A antagonist reducing CLint from 54 to 3 mL/min/kg; SD-254 deuteration halving venlafaxine metabolism; and the first clinical DDI demonstration where deuterated paroxetine (CTP-347) cut CYP2D6 inhibition from ~55-60% to ~15-20% vs. parent.

Critical Appraisal

Strengths: mechanistic depth spanning CYP to non-CYP (AO, MAO, UGT/SULT) enzymes, spanning data from HLM/MLM/RLM microsomes, hepatocytes, and in vivo PK across mouse, rat, dog, and human AO and non-CYP case studies. Limitations: no new data, corporate-sponsored selection bias, proprietary unpublished data (PF-562271 self-inactivation), and IADR-reactive-metabolite link still acknowledged as largely anecdotal by authors themselves. Notably, a proximal tubule-on-chip study now shows transporter-mediated clearance (metformin ER 2.94 under flow vs 0.75 static) is poorly captured by static microsomal assays Tubule-on-chip transporter dynamics, a blindspot the 2012 review does not address.

 BGPT Paper Review

Study Novelty

Comprehensive synthesis of established medicinal chemistry tactics with useful case studies, but largely consolidating known strategies rather than introducing novel concepts.

Scientific Quality

Well-organized, mechanistically grounded review with strong case studies and quantitative examples; limited by absence of new data, Pfizer corporate authorship, and some unpublished proprietary claims.

Study Generality

Strategies span CYP, AO, MAO, UGT/SULT, esterases, and reactive metabolite risks across multiple therapeutic areas, giving broad applicability to drug design.

Study Usefulness

Practical playbook for medicinal chemists and DMPK scientists; case studies like CTP-347 and ertugliflozin demonstrate actionable design principles.

Study Reproducibility

Review article synthesizing published examples with no new datasets; reproducibility limited to the quality of underlying primary studies.

Explanatory Depth

Mechanistic explanation is strong: details CYP3A4 Phe-cluster binding, AO catalytic cycle, MI complex formation with CYP heme, and isotope effects.